ストックスクリーナーアプリを入手
7.08
4.32%
-0.32
アフターアワーズ：
7.19
0.11
+1.55%
前日終値:
$7.40
開ける：
$7.415
24時間の取引高:
20,878
Relative Volume:
6.06
時価総額：
$132.41M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-17.67%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$7.08
$7.70
1週間の範囲:
$7.08
$8.78
52週間の値動き範囲:
$7.08
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
KLRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
7.08 | 132.41M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalaris Therapeutics Inc (KLRS) 最新ニュース
Kalaris Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Kalaris Therapeutics appoints new board chair - Investing.com Australia
Kalaris Therapeutics Appoints Leone Patterson to Board - TipRanks
Kalaris Therapeutics appoints new board member - Investing.com
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - MarketScreener
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - TradingView
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
Kalaris Therapeutics Completes Merger with AlloVir -March 19, 2025 at 04:18 am EDT - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Kalaris Secures $100M War Chest for Revolutionary Macular Degeneration Treatment - StockTitan
Shootin' the Bull about cattle feeders - The Globe and Mail
Kalaris and AlloVir Announce Stockholder Approval of Merger - VisionMonday.com
Stockholders Approve Game-Changing Kalaris-AlloVir Merger: What This Means for Retinal Disease Treatment - StockTitan
Allovir, Inc. SEC 10-K Report - TradingView
Allovir’s chief accounting officer sells $967 in stock - Investing.com India
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
Allovir director Vikas Sinha sells $1,225 in stock - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, CYTH, ALVR on Behalf of Shareholders - Finansavisen
AlloVir executes reverse stock split - Investing.com
Allovir stock plunges to 52-week low, touches $0.4 - Investing.com
AlloVir announces reverse stock split effective January 16 - Investing.com
AlloVir shareholders approve reverse stock split - Investing.com
AlloVir appoints new CEO following leadership shakeup - Investing.com
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - insights.citeline.com
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BioSpectrum Asia
Kalaris Therapeutics - The Pharma Letter
Kalaris to merge with AlloVir to become publicly traded company - World Pharmaceutical Frontiers
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire
Class Action Filed Against AlloVir, Inc. (ALVR)March 19, 2024 Deadline to JoinContact Levi & Korsinsky - MarketScreener
symbol__ Stock Quote Price and Forecast - CNN
Study examines connection between retinoblastoma and maternal smoking - Ophthalmology Times
Company unveils latest generation of assistive device for the legally blind - Ophthalmology Times
Ophthalmologist and former congressman John Cooksey dies at 80 - Ophthalmology Times
WVU receives $11 million COBRE grant for visual sciences research center - Ophthalmology Times
Faricimab FDA approval: Dr. Joshua Mali shares what this new therapy will mean to retina specialists - Ophthalmology Times
Bejeweled 17th century eyeglasses on block at Sotheby’s - Ophthalmology Times
AlloVir : Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective May 17, 2021 - MarketScreener
Lexicon Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:LXRX - Benzinga
4D Molecular Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FDMT - Benzinga
Kalaris Therapeutics Inc (KLRS) 財務データ
Kalaris Therapeutics Inc (KLRS) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):